Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 273

1.

Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial.

Courand PY, Pereira H, Del Giudice C, Gosse P, Monge M, Bobrie G, Delsart P, Mounier-Vehier C, Lantelme P, Denolle T, Dourmap C, Halimi JM, Girerd X, Rossignol P, Zannad F, Ormezzano O, Vaisse B, Herpin D, Ribstein J, Bouhanick B, Mourad JJ, Ferrari E, Chatellier G, Sapoval M, Azarine A, Azizi M; DENERHTN Investigators.

J Am Heart Assoc. 2017 Oct 10;6(10). pii: e007062. doi: 10.1161/JAHA.117.007062.

2.

Hypertension and pregnancy: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology.

Mounier-Vehier C, Amar J, Boivin JM, Denolle T, Fauvel JP, Plu-Bureau G, Tsatsaris V, Blacher J.

Fundam Clin Pharmacol. 2017 Feb;31(1):83-103. doi: 10.1111/fcp.12254. Epub 2016 Dec 21.

PMID:
27862304
3.
4.

Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial.

Azizi M, Pereira H, Hamdidouche I, Gosse P, Monge M, Bobrie G, Delsart P, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Girerd X, Michel Halimi J, Zannad F, Ormezzano O, Vaïsse B, Herpin D, Ribstein J, Chamontin B, Mourad JJ, Ferrari E, Plouin PF, Jullien V, Sapoval M, Chatellier G; DENERHTN Investigators.

Circulation. 2016 Sep 20;134(12):847-57. doi: 10.1161/CIRCULATIONAHA.116.022922. Epub 2016 Aug 30.

5.

[Hypertension during pregnancy: Epidemiology, definition].

Fauvel JP.

Presse Med. 2016 Jul-Aug;45(7-8 Pt 1):618-21. doi: 10.1016/j.lpm.2016.05.015. Epub 2016 Jul 28. French.

PMID:
27476778
6.

[Hypertension and pregnancy. Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology].

Mounier-Vehier C, Amar J, Boivin JM, Denolle T, Fauvel JP, Plu-Bureau G, Tsatsaris V, Blacher J.

Presse Med. 2016 Jul-Aug;45(7-8 Pt 1):682-99. doi: 10.1016/j.lpm.2016.05.012. Epub 2016 Jul 9. French.

PMID:
27402294
7.

Management of resistant hypertension: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology.

Denolle T, Chamontin B, Doll G, Fauvel JP, Girerd X, Herpin D, Vaïsse B, Villeneuve F, Halimi JM.

J Hum Hypertens. 2016 Nov;30(11):657-663. doi: 10.1038/jhh.2015.122. Epub 2016 Jan 28. Review.

PMID:
26818804
8.

Association of various blood pressure variables and vascular phenotypes with coronary, stroke and renal deaths: Potential implications for prevention.

Harbaoui B, Courand PY, Milon H, Fauvel JP, Khettab F, Mechtouff L, Cassar E, Girerd N, Lantelme P.

Atherosclerosis. 2015 Nov;243(1):161-8. doi: 10.1016/j.atherosclerosis.2015.09.011. Epub 2015 Sep 8.

PMID:
26386213
9.

A Bayesian Model to Describe Factors Influencing Trough Levels of Vancomycin in Hemodialysis Patients.

Sansot C, Kalbacher E, Lemoine S, Bourguignon L, Fauvel JP, Ducher M.

Nephron. 2015;131(2):131-7. doi: 10.1159/000439230. Epub 2015 Sep 17.

PMID:
26376164
10.

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group.

JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.

PMID:
26325557
11.

3D.03: INFLUENCE OF AORTIC ATHEROSCLEROSIS ON THE PROGNOSTIC VALUE OF POSTURAL BLOOD PRESSURE CHANGES.

Courand PY, Fay H, Harbaoui B, Khettab F, Fauvel JP, Bricca G, Milon H, Lantelme P.

J Hypertens. 2015 Jun;33 Suppl 1:e41. doi: 10.1097/01.hjh.0000467456.01139.e9.

PMID:
26102815
12.

Reliability of a Bayesian network to predict an elevated aldosterone-to-renin ratio.

Ducher M, Mounier-Véhier C, Lantelme P, Vaisse B, Baguet JP, Fauvel JP.

Arch Cardiovasc Dis. 2015 May;108(5):293-9. doi: 10.1016/j.acvd.2014.09.011. Epub 2015 Apr 6.

13.

Glycemic control according to glomerular filtration rate in patients with type 2 diabetes and overt nephropathy: a prospective observational study.

Joly D, Choukroun G, Combe C, Dussol B, Fauvel JP, Halimi JM, Quéré S, Fiquet B.

Diabetes Res Clin Pract. 2015 Apr;108(1):120-7. doi: 10.1016/j.diabres.2015.01.029. Epub 2015 Feb 12.

PMID:
25726333
14.

Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.

Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G; Renal Denervation for Hypertension (DENERHTN) investigators.

Lancet. 2015 May 16;385(9981):1957-65. doi: 10.1016/S0140-6736(14)61942-5. Epub 2015 Jan 26.

PMID:
25631070
15.

[Management of resistant hypertension. Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology].

Denolle T, Chamontin B, Doll G, Fauvel JP, Girerd X, Herpin D, Vaïsse B, Villeneuve F, Halimi JM.

Presse Med. 2014 Dec;43(12 Pt 1):1325-31. doi: 10.1016/j.lpm.2014.07.016. Epub 2014 Nov 20. French.

16.

Decreased plasma prorenin levels in primary aldosteronism: potential diagnostic implications.

Berge C, Courand PY, Harbaoui B, Paget V, Khettab F, Bricca G, Fauvel JP, Lantelme P.

J Hypertens. 2015 Jan;33(1):118-25. doi: 10.1097/HJH.0000000000000367.

PMID:
25333683
17.

[Renal denervation for treating hypertension: experience at the University Hospital in Lyon].

Courand PY, Dauphin R, Rouvière O, Paget V, Khettab F, Bergerot C, Harbaoui B, Bricca G, Fauvel JP, Lantelme P.

Ann Cardiol Angeiol (Paris). 2014 Jun;63(3):183-8. doi: 10.1016/j.ancard.2014.04.012. Epub 2014 Apr 26. French.

PMID:
24908520
18.

Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial.

Gueyffier F, Subtil F, Bejan-Angoulvant T, Zerbib Y, Baguet JP, Boivin JM, Mercier A, Leftheriotis G, Gagnol JP, Fauvel JP, Giraud C, Bricca G, Maucort-Boulch D, Erpeldinger S; IDEAL Trial Group.

J Hum Hypertens. 2015 Jan;29(1):22-7. doi: 10.1038/jhh.2014.29. Epub 2014 Apr 17.

PMID:
24739801
19.

Comparison of a Bayesian network with a logistic regression model to forecast IgA nephropathy.

Ducher M, Kalbacher E, Combarnous F, Finaz de Vilaine J, McGregor B, Fouque D, Fauvel JP.

Biomed Res Int. 2013;2013:686150. doi: 10.1155/2013/686150. Epub 2013 Nov 17.

20.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators.

N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9.

Supplemental Content

Loading ...
Support Center